Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30672641 | 0.77 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL15541944 | 0.73 | KDM1A (0.55) | KDM1AMAOA | |
| SCHEMBL15542258 | 0.73 | KDM1A (0.55) | KDM1AMAOA | |
| SCHEMBL6623618 | 0.73 | KDM1A (0.55) | KDM1AMAOA | |
| SCHEMBL2227972 | 0.71 | KDM1A (0.36) | KDM1AMAOA | |
| SCHEMBL27580178 | 0.71 | HSD11B1 (0.40) | HSD11B1ADORA2BADORA1 | |
| SCHEMBL28530963 | 0.71 | ADAM17 (0.42) | KDM1AMAOA | |
| SCHEMBL20519369 | 0.71 | ADORA2B (0.33) | HSD11B1NOS2ADORA2BADORA1 | |
| SCHEMBL5907270 | 0.70 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL31180426 | 0.70 | KCNH2 (0.33) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | HSD11B1 2158/4885NOS2 2634/4885KDM1A 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.